Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Georgetown University
Study ID
NCT02654639
Phase
PHASE2
Status
Terminated

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TAS-102 — DRUG
    TAS-102 Twice a day by mouth day 1-5 and 8-12
  • Bevacizumab — DRUG
    Bevacizumab by intravenous infusion once every 14 days

Study Details

Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC

Key Dates

First listed
Jan 13, 2016
Start date
Feb 29, 2016
Status verified
Apr 2018
Primary completion
Nov 30, 2017
Completion
Nov 30, 2017

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TAS-102 and Bevacizumab
    Oral TAS-102 and intravenous Bevacizumab.

Primary Outcome Measure

Length of Progression-Free Survival [ Time Frame: From the first occurrence of progression or death, whichever occurred first, assessed up to 2 years. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Georgetown UniversityWashington D.C.District of Columbia20007-

Find similar trials in Washington D.C., DC

By research site
Georgetown University· Washington D.C., DC

Related Studies